[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"binge-eating-disorder\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:binge-eating-disorder":28},{"pageToken":4,"total":5,"offset":6,"count":7,"results":8},null,30,0,25,[9,55,88,118,144,170,192,230,265,293,321,346,379,402,423,449,473,494,516,544,572,601,622,652,672],{"id":10,"slug":11,"hasResults":12,"nctId":13,"briefTitle":14,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":20,"targetDuration":4,"studyType":23,"phases":24,"briefSummary":26,"conditions":27,"keywords":37,"overallStatus":42,"whyStopped":4,"lastUpdateSubmitDate":43,"lastUpdatePostDateStruct":44,"startDateStruct":47,"completionDateStruct":49,"leadSponsor":51,"locationsCount":54},"100053868","halo-trial-high-medium-and-low-intensity-psychotherapy-for-binge-eating-disorder-100053868",false,"NCT07698132","HALO-TRIAL: High, Medium And LOw Intensity Psychotherapy for Binge Eating Disorder","HALO","Inclusion Criteria:\n\n* Binge Eating Disorder according to DSM-5 criteria\n* 18-65 years of age\n* Fluent Danish speaker\n\nExclusion Criteria:\n\n* Concurrent psychotherapeutic treatment\n* Use of weight loss medications within the last month (i.e., GLP-1 receptor antagonists)\n* Suicidal ideation or suicidality\n* Psychosis or psychotic disorders\n* Mania or bipolar disorder\n* Drug misuse disorder\n* Alcohol misuse disorder\n* Cluster B personality disorders in the severe range (diagnosed)\n* Dosage of Antidepressants, Antipsychotics and Stimulants must be stable for at least 6 months","ALL","18 Years","65 Years",{"count":21,"type":22},256,"ESTIMATED","INTERVENTIONAL",[25],"NA","The HALO trial is designed as a four-armed, assessor-blinded, fidelity-monitored randomized clinical trial. The goal of this randomized controlled study is to investigate the effectiveness of four different psychotherapy programs and to determine which one is most effective in reducing the number of binge-eating episodes in people with the eating disorder Binge Eating Disorder (BED), by directly comparing three intensities of Cognitive Behavioral Therapy-Enhanced against a manualized treatment as usual.\n\nParticipants will be asked to complete a 21-weeks randomized intervention and participate in follow up assesments.",[28,29,30,31,32,33,34,35,36],"Binge Eating Disorder","Binge Eating Episodes","Binge Eating\u002FLoss of Control Eating","Binge Eating Disorders","Binge Eating","Binge Eating Behaviour","Binge Eating Disorder Associated With Obesity","Eating Disorder Binge","Eating Disorders",[28,36,38,39,40,41],"Cognitive Behavioral Therapy","Psychotherapy","Randomized Controlled Trial","Evidence-based Psychiatry","RECRUITING","2026-07-07",{"date":45,"type":46},"2026-07-13","ACTUAL",{"date":48,"type":46},"2024-06-10",{"date":50,"type":22},"2032-12",{"name":52,"class":53},"Herlev and Gentofte Hospital","OTHER",1,{"id":56,"slug":57,"hasResults":12,"nctId":58,"briefTitle":59,"officialTitle":60,"acronym":61,"eligibilityCriteria":62,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":63,"enrollmentInfo":64,"targetDuration":4,"studyType":23,"phases":66,"briefSummary":67,"conditions":68,"keywords":72,"overallStatus":42,"whyStopped":4,"lastUpdateSubmitDate":80,"lastUpdatePostDateStruct":81,"startDateStruct":83,"completionDateStruct":84,"leadSponsor":86,"locationsCount":54},"100639845","eating-disorder-dynamic-intervention-100639845","NCT07600671","Eating Disorder Dynamic Intervention","Rapid Innovation of Precision Psychiatry Interventions Using Dynamic Systems Modeling and Ecological Quasi-Experiments","EDDI","Inclusion Criteria:\n\n1. Age 18-70\n2. At least 12 ED behaviors from the same behavioral category in the past 12 weeks (i.e., at least 12 binge eating episodes, at least 12 compensatory behaviors, and\u002For at least 12 instances of dietary restriction)\n3. Ownership of a smartphone\n4. Willingness to complete ecological momentary assessment (EMA) and sensor data collection\n5. Live in the United States\n6. Has a primary care provider or is willing to establish a primary care provider\n\nExclusion Criteria:\n\n1. Inability to fluently speak, read, and write in English\n2. Body mass index \\\u003C 17.5 kg\u002Fm2\n3. Medical complications of ED symptoms requiring immediate treatment\n4. Current ED-focused therapy\n5. Severe psychopathology (i.e., active suicidal ideation, psychosis, bipolar disorder, or substance use disorder) or intellectual disability inhibiting engagement in study protocols","70 Years",{"count":65,"type":22},170,[25],"The goal of this study is to develop and test a digital program to help people with eating disorders in their everyday lives. The program uses brief surveys and sensor data collected by smartphones to understand when someone may be at higher risk for behaviors like restricting food, binge eating, or using unhealthy weight control behaviors.",[36,69,70,28,71],"Anorexia Nervosa","Bulimia Nervosa","Other Specified Feeding or Eating Disorder",[73,74,75,76,77,78,79],"binge eating","eating problem","eating disorder","purging","restriction","weight control behavior","dieting","2026-06-29",{"date":82,"type":46},"2026-07-01",{"date":80,"type":46},{"date":85,"type":22},"2030-07-31",{"name":87,"class":53},"Trustees of Dartmouth College",{"id":89,"slug":90,"hasResults":12,"nctId":91,"briefTitle":92,"officialTitle":93,"acronym":94,"eligibilityCriteria":95,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":63,"enrollmentInfo":96,"targetDuration":4,"studyType":23,"phases":98,"briefSummary":100,"conditions":101,"keywords":103,"overallStatus":42,"whyStopped":4,"lastUpdateSubmitDate":109,"lastUpdatePostDateStruct":110,"startDateStruct":112,"completionDateStruct":114,"leadSponsor":116,"locationsCount":54},"100490314","phase-2-a-study-of-the-effects-of-oxytocin-in-adults-with-binge-eating-disorder-100490314","NCT05664516","A Study of the Effects of Oxytocin in Adults With Binge-eating Disorder","A Randomized, Double-blind, Placebo-controlled Study to Evaluate the Effects of Intranasal Oxytocin in Adults With Binge-eating Disorder","STROBE","Inclusion Criteria:\n\n* Males and females, 18-70 years old\n* BMI greater than or equal to 18.5\n* BED as assessed by Structured Clinical Interview for DSM-5 Disorders (SCID-5-RV) OR Other Specified Feeding or Eating Disorder (OSFED) - Binge-eating disorder (of low frequency and\u002For limited duration) (SCID-5-RV) OR Bulimia Nervosa (BN) through excessive exercise and\u002For fasting to avoid gaining weight after episodes of binge eating. For individuals with OSFED-BED, the frequency of subjective and objective binge eating episodes will meet the frequency (Criterion D) for BED.\n\nExclusion Criteria:\n\n* Substance use disorder active within the last 6 months, or clinical suspicion of ongoing substance use disorder at the discretion of the study clinician at the time of screening based on history and\u002For laboratory results\n* Medication changes that have not reached steady state concentration, measured by the equivalent of 5 half-lives of that medication\n* Use of medications for binge eating disorder or weight loss unless at a stable dose for at least 12 weeks\n* History of any of the following medical conditions: inflammatory bowel disease or untreated thyroid disease\n* Uncontrolled epilepsy (as defined by a seizure within the last 12 months)\n* Clinically relevant ventricular arrhythmias, coronary heart disease, known long QTc, and hypertrophic cardiomyopathy\n* Hematocrit \\>2% below normal\n* Hemoglobin A1c \\>8%\n* Use of insulin\n* ALT or AST \\>2.5 times upper limit of normal\n* Glomerular filtration rate \\\u003C 60 mL\u002Fmin\n* Hyponatremia. Note that, in order to be randomized, subjects must have Na ≥ 135 mEq\u002FL.\n* Pregnancy or breastfeeding\n* Unwilling to use a medically acceptable form of contraception throughout the study period (female of child-bearing potential only)\n* History of psychosis or active suicidal ideation\n* Major depressive disorder likely to require initiation or change in active treatment\n* Borderline personality disorder as assessed by the McLean Screening Instrument for Borderline Personality Disorder (MSI-BPD)\n* Current nicotine use, unless stable use for at least 12 weeks.\n* Participation in any clinical study involving an investigational drug, device, or biologic within 1 month of randomization\n* Any significant illness, condition, or medication that the Investigator determines could interfere with study participation and impact data collection or subject safety",{"count":97,"type":22},60,[99],"PHASE2","This study evaluates the impact of intranasal oxytocin vs placebo in patients with binge eating disorder or episodes of binging. We hypothesize that 8 weeks of intranasal oxytocin vs placebo will improve clinical outcomes \\[reduction in bingeing frequency\\], and have a satisfactory safety and tolerability profile. We will also explore the predictive value of changes in homeostatic appetite, reward sensitivity, and impulse control, the identified underlying mediators, as assessed 4 weeks into the intervention, for treatment success after 8 weeks of the intervention.",[102],"Binge-eating Disorder",[104,105,106,107,108],"Binge","Binge-eating disorder","Oxytocin","Over-eating","Impulse Control","2026-05-26",{"date":111,"type":46},"2026-05-28",{"date":113,"type":46},"2023-03-07",{"date":115,"type":22},"2026-12",{"name":117,"class":53},"Massachusetts General Hospital",{"id":119,"slug":120,"hasResults":12,"nctId":121,"briefTitle":122,"officialTitle":123,"acronym":124,"eligibilityCriteria":125,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":126,"targetDuration":4,"studyType":23,"phases":127,"briefSummary":128,"conditions":129,"keywords":130,"overallStatus":42,"whyStopped":4,"lastUpdateSubmitDate":135,"lastUpdatePostDateStruct":136,"startDateStruct":138,"completionDateStruct":140,"leadSponsor":142,"locationsCount":54},"100626464","cor-protocol-for-the-treatment-of-binge-eating-in-chilean-adults-cor-100626464","NCT07435974","COR Protocol for the Treatment of Binge Eating in Chilean Adults (COR)","A Pilot Study on the Feasibility and Acceptability of the COR (Body Compassion-Emotional Regulation-Conscious Reconnection With Eating) Protocol for Addressing Binge Eating in Chilean Adults","COR","Inclusion Criteria:\n\n* Adults aged 18 years or older.\n* Overweight or obesity, based on self-report.\n* At least three binge-eating episodes in the past 30 days, associated with psychological distress.\n* The presence of chronic medical conditions commonly associated with overweight or obesity (e.g., hypothyroidism, hyperthyroidism, dyslipidemia, hypertension, type 2 diabetes mellitus, or polycystic ovary syndrome) is permitted, provided that such conditions are medically stable.\n* If present, chronic medical conditions must be medically stable, defined as:\n* stable medical treatment for at least 12 weeks,\n* no recent changes in medication,\n* no acute clinical decompensation or recent major cardiovascular events,\n* at least one related medical follow-up visit in the past 12 months.\n* If present, psychopharmacological treatment must be stable, defined as no changes in medication type or dosage during the 12 weeks prior to enrollment.\n* Daily access to the internet and to a computer or smartphone that allows participation in online sessions and assessments.\n\nExclusion Criteria:\n\n* Current compensatory behaviors associated with binge eating, such as self-induced vomiting and\u002For regular use of laxatives, within the past 60 days.\n\n  * Pregnancy or breastfeeding at the time of the initial assessment.\n  * History of bariatric surgery.\n  * Active suicidal ideation\n  * Current symptoms consistent with severe mental disorders, such as psychotic disorders, bipolar disorder, complex post-traumatic stress disorder, or severe personality disorders, when associated with marked functional impairment or the need for specialized or higher-intensity clinical care.\n  * Current substance use pattern that, due to its severity or functional impact, requires specialized clinical treatment.\n  * Ongoing psychological and\u002For nutritional treatment at the time of enrollment, defined as regular sessions or an active treatment plan, regardless of treatment focus or therapeutic approach.\n  * Presence of active or medically unstable conditions, characterized by clinically significant symptoms, lack of medical follow-up, or recent changes in medication, that could interfere with participation in the intervention or substantially affect eating behavior or mood.\n  * Significant functional impairment that, in the clinical judgment of the research team, would limit the participant's ability to engage safely and consistently in the intervention.",{"count":5,"type":22},[25],"The goal of this clinical study is to learn whether a brief online psychological program called COR can be delivered in a feasible and acceptable way for adults who experience recurrent binge eating.\n\nThe main questions this study aims to answer are:\n\n* Is the COR program acceptable to participants, in terms of satisfaction, adherence, and dropout rates?\n* Is the COR program feasible to deliver online, including recruitment, retention, and completion of sessions and questionnaires?\n* Do participants show preliminary changes over time in binge eating-related distress and emotional well-being?\n\nParticipants in this study are adults who experience recurrent episodes of binge eating. They will take part in an individual online intervention that includes eight weekly sessions, a brief pre-session, and a follow-up session one month after the end of treatment.\n\nDuring the study, participants will:\n\n* Attend weekly online sessions focused on understanding binge eating, emotions, and the relationship with food and the body\n* Practice simple exercises to help manage emotional distress and food-related urges\n* Complete short questionnaires before, during, and after the intervention to describe their experiences\n\nThe information from this study will help researchers understand whether this type of intervention can be used in future, larger studies and in real-world clinical settings.",[28,32],[131,28,132,133,134],"Binge eating","Body compassion","Emotion regulation","Intuitive eating","2026-04-20",{"date":137,"type":46},"2026-04-22",{"date":139,"type":46},"2026-04-01",{"date":141,"type":22},"2026-07-30",{"name":143,"class":53},"Universidad Catolica de Temuco",{"id":145,"slug":146,"hasResults":12,"nctId":147,"briefTitle":148,"officialTitle":149,"acronym":4,"eligibilityCriteria":150,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":151,"targetDuration":4,"studyType":23,"phases":153,"briefSummary":154,"conditions":155,"keywords":157,"overallStatus":42,"whyStopped":4,"lastUpdateSubmitDate":162,"lastUpdatePostDateStruct":163,"startDateStruct":164,"completionDateStruct":166,"leadSponsor":168,"locationsCount":54},"100582089","use-of-circadian-reset-technology-to-alter-rem-sleep-and-appetitive-control-in-patients-with-binge-eating-disorder-100582089","NCT06858774","Use of Circadian Reset Technology to Alter REM Sleep and Appetitive Control in Patients With Binge Eating Disorder","Use of Circadian Reset Technology to Alter REM Sleep and Appetitive Control Through Improved Network Connectivity in Brain in Patients With Binge Eating Disorder","Inclusion Criteria:\n\n* Ages 18+\n* Diagnosed with Binge Eating Disorder using EDA-5\n* English-speaking\n\nExclusion Criteria:\n\n* Pregnancy\n* Acute suicide risk\u002Factive suicidal ideation\n* PSQI score \\\u003C5 indicating good sleep quality\n* A condition that may create a risk while using the VR headset including risk of falls, seizures, a heart condition, migraines, an eye or vision condition, or an inner ear condition.",{"count":152,"type":22},40,[25],"This project includes testing circadian reset technology (CRT) on frequency of binge eating in a sample of 40 individuals with binge eating disorder. Participants will be randomized to one of two groups. Both groups use a virtual reality (VR) headset for 10 minutes (5 upon waking, 5 before sleep) daily for 1 month. One group will use the CRT software on the headset and the other group will use a software intended to be a control. Measures will be taken at baseline and 1-month. The researchers anticipate that use of CRT will improve sleep quality leading to increased appetitive control.",[156],"Binge-Eating Disorder",[28,158,159,160,161],"Eating Disorder","Eating Disorder Treatment","Circadian Rhythm Technology","Virtual Reality","2026-04-15",{"date":135,"type":46},{"date":165,"type":46},"2025-05-13",{"date":167,"type":22},"2026-11",{"name":169,"class":53},"Icahn School of Medicine at Mount Sinai",{"id":171,"slug":172,"hasResults":12,"nctId":173,"briefTitle":174,"officialTitle":175,"acronym":4,"eligibilityCriteria":176,"healthyVolunteers":12,"sex":17,"minAge":177,"maxAge":178,"enrollmentInfo":179,"targetDuration":4,"studyType":23,"phases":181,"briefSummary":182,"conditions":183,"keywords":4,"overallStatus":42,"whyStopped":4,"lastUpdateSubmitDate":184,"lastUpdatePostDateStruct":185,"startDateStruct":186,"completionDateStruct":188,"leadSponsor":190,"locationsCount":54},"100611209","developing-an-artificial-intelligence-ai-chatbot-for-adolescents-and-young-adults-with-eating-disorders-100611209","NCT07237607","Developing an Artificial Intelligence (AI) Chatbot for Adolescents and Young Adults With Eating Disorders","Developing an Artificial Intelligence (AI)-Powered Exposure Therapy Chatbot for Adolescents and Young Adults With Eating Disorders","Inclusion Criteria:\n\n* Age is between or equal to 12-26 years\n* Admitted to the Penn State Health Eating Disorder Partial Hospital Program (PHP) or Intensive Outpatient Program (IOP)\n* Have a personal smartphone\n* Have a diagnosis of anorexia nervosa (AN), bulimia nervosa (BN), binge-eating disorder (BED), or other specified feeding or eating disorder (OSFED)\n* Be English speaking\n\nExclusion Criteria:\n\n* Diagnosis of avoidant\u002Frestrictive food intake disorder (ARFID)\n* Have acute suicidality\n* Diagnosis of an intellectual disability","12 Years","26 Years",{"count":180,"type":22},20,[25],"The goal of this study is to develop and refine an artificial intelligence (AI)-powered Exposure Therapy for Eating Disorders chatbot web-app that effectively engages adolescents and young adults and decreases anxiety about weight gain. Participants will use the web-app as a supplemental therapeutic tool during their first six weeks of treatment in a Partial Hospitalization Program. Participants will complete assessments every two weeks, including: (1) semi-structured interviews about their experience with the chatbot web-app; (2) implementation outcome measures (e.g., feasibility, usability, acceptability); and (3) anxiety about weight gain.",[36,69,70,156],"2026-04-14",{"date":162,"type":46},{"date":187,"type":46},"2026-03-23",{"date":189,"type":22},"2027-06-30",{"name":191,"class":53},"Milton S. Hershey Medical Center",{"id":193,"slug":194,"hasResults":12,"nctId":195,"briefTitle":196,"officialTitle":197,"acronym":198,"eligibilityCriteria":199,"healthyVolunteers":200,"sex":17,"minAge":201,"maxAge":202,"enrollmentInfo":203,"targetDuration":4,"studyType":23,"phases":205,"briefSummary":206,"conditions":207,"keywords":214,"overallStatus":219,"whyStopped":4,"lastUpdateSubmitDate":220,"lastUpdatePostDateStruct":221,"startDateStruct":223,"completionDateStruct":225,"leadSponsor":227,"locationsCount":229},"100616125","effectiveness-of-a-10-week-multicomponent-intervention-combined-with-parent-education-on-binge-eating-behavior-in-children-and-adolescents-100616125","NCT07301541","Effectiveness of a 10-week Multicomponent Intervention Combined With Parent Education on Binge Eating Behavior in Children and Adolescents","Effectiveness of a 10-week Multicomponent Intervention Combined With Parent Education on Binge Eating Behavior in Children and Adolescents: a Randomized Controlled Trial With Long-term Follow-up","STOB","Inclusion Criteria:\n\n* Attending the camp in Hobro or Fjordmark from January 2027 to December 2027\n* 7-14 years of age at recruitment\n* Participants must have written informed consent from parent\u002Fguardian before camp to participate\n* At least one parent\u002Fguardian submit written informed consent to participate in the study with their child\n\nExclusion Criteria:\n\n* A medical condition affecting dietary intake and\u002For eating behavior\n* Taking weight loss medication\n* The parent\u002Fguardian don't understand the written informed consent\n* Participant or parent\u002Fguardian are unwilling to or unable to comply with the study protocol and instructions given by the study staff.",true,"7 Years","14 Years",{"count":204,"type":22},200,[25],"The main purpose is to investigate the effectiveness of a 10-week multicomponent camp intervention to reduce BE behavior in children and adolescents and explore in a randomized controlled setting if a parent-based BED-intervention has any add-on effect, attenuating the development of BE behavior in this sample. The study will include an initial follow-up assessment scheduled 10-12 weeks after camp completion and plans for long-term follow-up assessments one, three and five years after inclusion.\n\nOverall, we hypothesize that the multicomponent camp intervention will effectively reduce BE behavior in children and adolescents. Furthermore, we hypothesize that participants whose parents are randomized to receive the parental BED intervention will show a lower prevalence of BE behavior one year after the camp intervention compared with children whose parents receive standard care.",[28,32,208,209,210,211,212,213],"Loss of Control Eating","Overweight , Obesity","Children","Childhood Obesity","Screening","BED",[131,215,216,210,217,218,213,212],"Binge eating disorder","Lifestyle intervention","Loss of control eating","Adolescents","NOT_YET_RECRUITING","2026-04-07",{"date":222,"type":46},"2026-04-13",{"date":224,"type":22},"2027-01",{"date":226,"type":22},"2036-01",{"name":228,"class":53},"University of Aarhus",2,{"id":231,"slug":232,"hasResults":12,"nctId":233,"briefTitle":234,"officialTitle":235,"acronym":4,"eligibilityCriteria":236,"healthyVolunteers":12,"sex":17,"minAge":237,"maxAge":238,"enrollmentInfo":239,"targetDuration":4,"studyType":23,"phases":241,"briefSummary":242,"conditions":243,"keywords":247,"overallStatus":42,"whyStopped":4,"lastUpdateSubmitDate":256,"lastUpdatePostDateStruct":257,"startDateStruct":259,"completionDateStruct":261,"leadSponsor":263,"locationsCount":229},"100480801","study-comparing-acceptance-and-commitment-therapy-to-supportive-diabetes-counseling-and-a-waitlist-control-for-eating-disorders-in-type-1-diabetes-100480801","NCT05540704","Study Comparing Acceptance and Commitment Therapy to Supportive Diabetes Counseling and a Waitlist Control for Eating Disorders in Type 1 Diabetes","Changing the T1DE (Type 1 Diabetes Eating Disorders): A Randomized Controlled Trial Comparing Acceptance and Commitment Therapy (ACT) to Supportive Diabetes Counseling and a Waitlist Control","Primary Cohort\n\nInclusion Criteria:\n\n* 16-50 years of age\n* Diagnosis of Type 1 diabetes\n* Eating disorder characterized by binge eating and\u002For problematic weight control behaviors, including withholding insulin (Bulimia Nervosa, Binge Eating and Purging Disorder spectrum diagnoses)\n* Independently manages diabetes (not reliant on a caregiver)\n\nExpansion Cohort\n\nInclusion Criteria:\n\n* 16-50 years of age\n* Diagnosis of Type 1 diabetes\n* DEPR-R score \\>=20 but does not meet criteria for the primary cohort\n\nPrimary and Expansion Cohort\n\nExclusion Criteria:\n\n* Active suicidal ideation\n* Diagnosis of Avoidant Restrictive Food Intake Disorder or Anorexia Nervosa spectrum diagnoses\n* Hypoglycemic unawareness as assessed by the Gold Method and multiple severe episodes of hypoglycemia requiring 3rd party assistance in the last 2 years\n* Current substance abuse disorder or current or past psychotic disorder\n* NonEnglish speaking","16 Years","50 Years",{"count":240,"type":22},235,[25],"The goal of this clinical trial is to test whether a new intervention works to treat eating disorders in type 1 diabetes. Participants are assigned to one of the following: (1) Acceptance and Commitment Therapy (ACT), (2) Supportive Diabetes Counseling, or (3) a 6-month Waitlist Control. Participants in the ACT and Supportive Diabetes Counseling conditions complete 12 sessions over 12-16 weeks and use their mobile phone between sessions to increase engagement and reinforce learning.\n\nThe main questions are:\n\nDoes treatment improve glycemic levels, eating disorder symptoms, diabetes management and diabetes distress?\n\nDoes one treatment do better than the other?\n\nHow do the treatments work, if they work, and for whom?\n\nParticipants complete assessments that include wearing a continuous glucose sensor and activity watch, and get a blood draw to determine HbA1c. They also complete diagnostic interviews, surveys and computer tests of attention and things like heart rate and reaction time. These assessments help us better understand the types of changes that are happening and how they might influence health and well-being.",[244,36,245,246,156],"Type 1 Diabetes","Disordered Eating Behaviors","Purging (Eating Disorders)",[248,249,250,251,252,253,254,255],"glycemic control","disordered eating behavior","eating disorders","type 1 diabetes","acceptance and commitment therapy","diabetes counseling","mhealth","psychological flexibility","2026-02-23",{"date":258,"type":46},"2026-02-25",{"date":260,"type":46},"2023-04-04",{"date":262,"type":22},"2027-09",{"name":264,"class":53},"Duke University",{"id":266,"slug":267,"hasResults":12,"nctId":268,"briefTitle":269,"officialTitle":270,"acronym":271,"eligibilityCriteria":272,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":273,"targetDuration":4,"studyType":23,"phases":275,"briefSummary":276,"conditions":277,"keywords":279,"overallStatus":42,"whyStopped":4,"lastUpdateSubmitDate":284,"lastUpdatePostDateStruct":285,"startDateStruct":287,"completionDateStruct":289,"leadSponsor":291,"locationsCount":54},"100597595","building-healthy-eating-and-self-esteem-together-for-university-students-100597595","NCT07060534","Building Healthy Eating and Self-Esteem Together for University Students","Building Healthy Eating and Self-Esteem Together for University Students (BEST-U): A Pilot Randomized Controlled Trial of an mHealth Intervention for Binge-Spectrum Disorders","BEST-U","Inclusion Criteria:\n\n* Age ≥ 18 years.\n* Student enrolled at KU.\n* Bulimia nervosa (BN) or binge-eating disorder (BED) (or sub-threshold BN or BED).\n* Access to a smartphone.\n* No uncorrected vision problems that would interfere with ability to participate in the study.\n* Students taking psychotropic medications must be on a stable therapeutic dose for four weeks prior to study enrollment.\n* Able to read and speak fluent English.\n\nExclusion Criteria:\n\n* Presence of current moderate\u002Fsevere suicidal ideation with active intent.\n* Significant psychopathology that could interfere with treatment (e.g., current substance-use disorder or psychosis).\n* Medical conditions or medications that could interfere with treatment (e.g., Type 1 diabetes mellitus, cancer, current pregnancy or nursing, taking corticosteroids, etc.).\n* Lab abnormalities indicating medical instability (e.g., low heart rate, electrolyte disturbance, acute medical complications of malnutrition) or another medical problem that would prevent outpatient care as determined through physical health assessment by the student's local clinician.\n* Already receiving therapy for an ED.\n* Positive screen for anorexia nervosa (AN), atypical AN (AAN), and\u002For low body weight (i.e., BMI \\\u003C 19.5) or avoidant and restrictive food intake disorder (ARFID).",{"count":274,"type":22},74,[25],"Eating disorders (EDs) are a critical concern on college campuses. Moreover, since the COVID-19 pandemic, ED prevalence has increased by 62% in university women and 140% in university men. Resources are inadequate to meet demand, leading to delays in students' access to treatment. Untreated (or poorly treated) EDs result in greater healthcare utilization and costs to students, as well as lower academic achievement and increased psychiatric disability and mortality, suggesting a critical need for quality ED treatment on university campuses and to rethink treatment delivery. One way to address this gap in care delivery is to improve treatment accessibility and scalability, such as dissemination via mobile apps. Guided self-help Cognitive Behavior Therapy (CBT-gsh) is a cost-effective option that can be delivered by non-traditional service providers, such as nurses and physicians. Our scientific premise is that the mHealth CBT-gsh app, Building Healthy Eating and Self-Esteem Together for University Students (BEST-U), will lead to reductions in binge eating (primary outcome) through reductions in dietary restraint and weight\u002Fshape concerns (target mechanisms). Prior to implementing BEST-U at other universities, we need to test the intervention in a real-world setting with the end goal of disseminating at scale. Our objectives are to: 1) conduct an effectiveness test of BEST-U compared to a similar dose of present-centered therapy (PCT) in students with non-low weight binge-spectrum EDs and 2) test target mechanisms that lead to changes in binge eating. To accomplish our objectives, we will test the following specific aims: 1) conduct an RCT of BEST-U (N=37) compared to a similar dose of PCT (N=37) in students with non-low weight binge-spectrum EDs; 2) test target mechanisms that lead to changes in binge eating and other ED symptoms; and 3) characterize barriers and facilitators to implementation across two campuses. Our exploratory aim will test food reinforcement and food-choice impulsivity as potential target mechanisms or response moderators of rapid response in binge eating. Given that few studies have identified underlying mechanisms that explain how CBT-gsh works and for whom, this study may lead to improved ability to tailor or modify existing CBT-gsh or lead to novel intervention development for students who are unlikely to respond rapidly (or at all) to first line CBT interventions for EDs.",[278,156],"Eating Disorders (Excluding Anorexia Nervosa)",[280,281,105,282,283],"Eating disorders","Bulimia nervosa","College Students","Purging disorder","2026-01-13",{"date":286,"type":46},"2026-01-14",{"date":288,"type":22},"2026-06-23",{"date":290,"type":22},"2027-12-31",{"name":292,"class":53},"University of Kansas",{"id":294,"slug":295,"hasResults":12,"nctId":296,"briefTitle":297,"officialTitle":298,"acronym":299,"eligibilityCriteria":300,"healthyVolunteers":12,"sex":17,"minAge":237,"maxAge":4,"enrollmentInfo":301,"targetDuration":4,"studyType":23,"phases":303,"briefSummary":304,"conditions":305,"keywords":307,"overallStatus":42,"whyStopped":4,"lastUpdateSubmitDate":312,"lastUpdatePostDateStruct":313,"startDateStruct":315,"completionDateStruct":317,"leadSponsor":319,"locationsCount":54},"100598781","training-app-for-inhibitory-control-towards-food-100598781","NCT07075952","Training App for Inhibitory Control Towards Food","Testing FoodTraining (FoodT): A Mobile App to Train Inhibitory Control Towards Food and Augment Standard Treatment for People With Eating and Weight Disorders","FoodT-RCT","Inclusion Criteria:\n\n* BMI in the obesity range (\\>30) or a clinician-formulated diagnosis of binge eating disorder or bulimia nervosa;\n* knowledge of Italian or English;\n* access to a mobile device (e.g. smartphone, tablet).\n\nExclusion Criteria:\n\n* visual impairment not corrected by glasses\n* a diagnosis of psychosis;\n* intellectual disability.",{"count":302,"type":22},113,[25],"The aim of this project is to test the feasibility, acceptability and clinical impact of a mobile app-based intervention (FoodTraining) to strengthen food-related inhibitory control over 4 weeks, in a sample of people with eating or weight disorders (i.e. obesity, binge-eating disorder (BED), or bulimia nervosa (BN)) receiving standard outpatient treatment (i.e., treatment as usual (TAU) encompassing guided self-help or psychotherapy, pharmacological therapy or diet). The training will be offered in addition to TAU (experimental group) and compared to TAU alone (control group).\n\nParticipants will complete questionnaires to measure eating behaviour, eating disorder psychopathology, symptoms of anxiety, depression and stress, social functioning and quality of life at baseline, 4 and 8 weeks. They will also complete momentary assessments using a mobile application (FoodTracker) to report on food intake along with related thoughts, emotions, and behaviours and will wear small, non-invasive sensors to track real-time fluctuations in glucose levels for 15 days.\n\nParticipants will also perform a food-related go-no go task and a food-related temporal discounting task at baseline, 4 and 8 weeks.\n\nFinally, this study will pilot the use of a semi-structured interview to characterise the history of weight, the appetite system, eating-related habits in the family and learning of eating behaviours and attitudes in people with eating or weight disorders.",[306,70,156],"Obesity &Amp; Overweight",[308,309,310,70,156,311],"App","Training","Inhibitory control","Obesity","2025-12-22",{"date":314,"type":46},"2025-12-30",{"date":316,"type":46},"2025-10-01",{"date":318,"type":22},"2027-03",{"name":320,"class":53},"University of Padova",{"id":322,"slug":323,"hasResults":12,"nctId":324,"briefTitle":325,"officialTitle":326,"acronym":327,"eligibilityCriteria":328,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":329,"targetDuration":4,"studyType":23,"phases":331,"briefSummary":332,"conditions":333,"keywords":334,"overallStatus":219,"whyStopped":4,"lastUpdateSubmitDate":337,"lastUpdatePostDateStruct":338,"startDateStruct":340,"completionDateStruct":342,"leadSponsor":344,"locationsCount":54},"100615658","sleep-and-activity-for-eating-disorders-100615658","NCT07295470","Sleep and Activity For Eating Disorders","Sleep and Activity For Eating Disorders (SAFE): a Cross-sectional and Prospective Study on the Sleep Parameters.","SAFE","Inclusion Criteria:\n\n* a) Age over 18 and under 65;\n* b) Diagnosis of anorexia nervosa, bulimia nervosa, or binge-eating disorder, as indicated by DSM-5-TR criteria;\n* c) Adherence to the rehabilitation program.\n\nExclusion Criteria:\n\n* a) Presence of severe bradycardia (BPM \\\u003C 35);\n* b) Severe malnutrition (BMI \\\u003C 10);\n* c) Presence of severe psychopathology other than the eating disorder (e.g., schizophrenia);\n* d) Need to modify psychotropic or sleep-inducing pharmacological therapy during the rehabilitation program.",{"count":330,"type":22},75,[25],"The SAFE (i.e., Sleep and Activity For Eating disorders) study aims to investigate the characteristics of sleep, daytime activity, and circadian rhythms in a sample of patients with eating disorders-specifically anorexia nervosa, bulimia nervosa, and binge-eating disorder-as well as the relationship between these variables and physiological parameters (i.e., body mass index, hormone levels, blood chemistry parameters) and psychological parameters (i.e., levels of depression and anxiety, body image, eating-disorder symptoms).",[36,69,70,28],[335,336,280],"Sleep","Circadian rhythms","2025-12-16",{"date":339,"type":46},"2025-12-19",{"date":341,"type":22},"2026-02",{"date":343,"type":22},"2027-07",{"name":345,"class":53},"Istituto Auxologico Italiano",{"id":347,"slug":348,"hasResults":12,"nctId":349,"briefTitle":350,"officialTitle":351,"acronym":352,"eligibilityCriteria":353,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":354,"enrollmentInfo":355,"targetDuration":4,"studyType":23,"phases":357,"briefSummary":359,"conditions":360,"keywords":361,"overallStatus":42,"whyStopped":4,"lastUpdateSubmitDate":368,"lastUpdatePostDateStruct":369,"startDateStruct":371,"completionDateStruct":373,"leadSponsor":375,"locationsCount":378},"100547858","phase-3-elucidating-taar-1-dopamine-and-norepinephrine-in-binge-eating-disorder-using-solriamfetol-100547858","NCT06413433","Elucidating TAAR-1, Dopamine, and Norepinephrine in Binge Eating Disorder Using Solriamfetol","A Phase 3, Randomized, Double-blind, Placebo-Controlled Trial of Solriamfetol in Adults With Binge Eating Disorder (BED)","ENGAGE","Inclusion Criteria:\n\n* Primary diagnosis of BED according to DSM-5 criteria.\n* Provides written informed consent to participate in the study before the conduct of any study procedures.\n* Male or female, aged 18 to 55 inclusive.\n\nExclusion Criteria:\n\n* Prior exposure to solriamfetol\u002FSunosi, through either a clinical study or prescription.\n* Unable to comply with study procedures.\n* Medically inappropriate for study participation in the opinion of the investigator.","55 Years",{"count":356,"type":22},450,[358],"PHASE3","ENGAGE (Elucidating TAAR-1, Dopamine, and Norepinephrine in Binge Eating Disorder Using Solriamfetol) is a Phase 3, randomized, double-blind, placebo-controlled, multicenter trial to assess the efficacy and safety of solriamfetol for the treatment of binge eating disorder (BED) in adults.",[156],[215,213,362,363,364,365,366,367],"Solriamfetol","Sunosi","Axsome","Non-stimulant therapy","Dopamine norepinephrine reuptake inhibitor","Trace amine-associated receptor 1 (TAAR1) agonist","2025-11-20",{"date":370,"type":46},"2025-11-21",{"date":372,"type":46},"2024-04-26",{"date":374,"type":22},"2025-12",{"name":376,"class":377},"Axsome Therapeutics, Inc.","INDUSTRY",45,{"id":380,"slug":381,"hasResults":12,"nctId":382,"briefTitle":383,"officialTitle":384,"acronym":385,"eligibilityCriteria":386,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":387,"targetDuration":4,"studyType":23,"phases":389,"briefSummary":390,"conditions":391,"keywords":4,"overallStatus":42,"whyStopped":4,"lastUpdateSubmitDate":393,"lastUpdatePostDateStruct":394,"startDateStruct":396,"completionDateStruct":398,"leadSponsor":399,"locationsCount":54},"100462625","building-an-equitable-and-accessible-system-of-eating-disorder-care-for-va-dod-and-underrepresented-americans-100462625","NCT05304104","Building an Equitable and Accessible System of Eating Disorder Care for VA, DoD, and Underrepresented Americans","Building an Equitable and Accessible System of Eating Disorder Care for VA, DoD, and Underrepresented Americans With Eating Disorders (EASED Study)","EASED","Inclusion Criteria:\n\n* Aged 18 and older\n* Presence of Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition (DSM-5) Bulimia Nervosa (BN) or Binge Eating Disorder (BED)\n* Veteran Health Administration (VHA) user\n\nExclusion Criteria:\n\n* Active psychosis or high acute risk for suicide\n* Medical or psychiatric illness, or cognitive deficits, that interfere with providing consent, completing assessments, or engaging in treatment for eating disorders\n* Pregnancy or lactation\n* Patients with suspected Anorexia or Atypical Anorexia will be excluded and referred to other VA care services",{"count":388,"type":22},144,[25],"When untreated, eating disorders present with tremendous burdens to affected active duty Service members and Veterans and their families, and are very costly to the DoD and VA healthcare system. A comparative effectiveness study with state-of-the-art virtual treatment for BN and BED specifically adapted for testing with the Veteran population and other underrepresented eating disorder populations will lead to major improvements in clinical outcomes. The treatment will be integrated with VA's newest telehealth technology to profoundly enhance access to care anywhere, at any time. This trial of therapist-led and self-help CBT treatments, combined with our expert panel methods to inform VA Clinical Practice Guidelines for Eating Disorders and plans for dissemination, will accelerate the pace for the transition of results both for large-scale deployment in the VA system and for real-world impact among diverse and underrepresented eating disorder populations.",[156,70,392,38],"Veterans Health","2025-11-19",{"date":395,"type":46},"2025-11-25",{"date":397,"type":46},"2022-04-22",{"date":374,"type":22},{"name":400,"class":401},"VA Connecticut Healthcare System","FED",{"id":403,"slug":404,"hasResults":12,"nctId":405,"briefTitle":406,"officialTitle":407,"acronym":4,"eligibilityCriteria":408,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":63,"enrollmentInfo":409,"targetDuration":4,"studyType":23,"phases":410,"briefSummary":411,"conditions":412,"keywords":413,"overallStatus":42,"whyStopped":4,"lastUpdateSubmitDate":415,"lastUpdatePostDateStruct":416,"startDateStruct":418,"completionDateStruct":419,"leadSponsor":421,"locationsCount":54},"100609291","combining-digital-cognitive-behavior-therapy-with-mindfulness-training-for-binge-eating-disorder-100609291","NCT07212673","Combining Digital Cognitive-behavior Therapy With Mindfulness Training for Binge Eating Disorder","Combining Digital Cognitive-behavior Therapy With Mindfulness Training for Binge Eating Disorder: a Feasibility Randomized Controlled Trial","Inclusion Criteria:\n\n* age 18 years or older\n* ability to speak English fluently\n* meeting DSM-5 criteria for current BED (i.e., in the past three months)\n* willing and able to commit to the entire study protocol\n\nExclusion Criteria:\n\n* a BMI below 18.5\n* requiring immediate treatment for medical complications\n* having current anorexia or bulimia nervosa or purging behaviors within the past year\n* being pregnant or breast-feeding\n* experiencing other severe psychopathology or medical illness that would limit the participants' ability to comply with the demands of the current study (e.g. active suicidal risk, active psychotic disorder, unmedicated bipolar disorder, severe substance use disorder, cancer)\n* currently receiving BED or weight loss treatment (treatment for other conditions will be allowed, as long as the treatment is not mindfulness-based)\n* currently taking medications for weight loss, or beginning medications that affect eating\u002Fweight within the last six months.",{"count":152,"type":22},[25],"The investigators will evaluate the acceptability and feasibility of a 16-session digital mindfulness-based and cognitive behavioral therapy (CBT) intervention for binge eating disorder (BED) + coached self-monitoring vs. a coached self-monitoring intervention. This study is a pilot randomized controlled trial.",[28],[73,75,414],"obesity","2025-11-02",{"date":417,"type":46},"2025-11-04",{"date":415,"type":46},{"date":420,"type":22},"2027-10-01",{"name":422,"class":53},"Yeshiva University",{"id":424,"slug":425,"hasResults":12,"nctId":426,"briefTitle":427,"officialTitle":428,"acronym":429,"eligibilityCriteria":430,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":431,"targetDuration":4,"studyType":23,"phases":433,"briefSummary":434,"conditions":435,"keywords":437,"overallStatus":42,"whyStopped":4,"lastUpdateSubmitDate":441,"lastUpdatePostDateStruct":442,"startDateStruct":444,"completionDateStruct":445,"leadSponsor":447,"locationsCount":54},"100581214","phase-2-efficacy-and-safety-of-tirzepatide-versus-placebo-or-lisdexamfetamine-dimesylate-for-binge-eating-disorder-100581214","NCT06847399","Efficacy and Safety of Tirzepatide Versus Placebo or Lisdexamfetamine Dimesylate for Binge-Eating Disorder","Efficacy and Safety of Tirzepatide Versus Placebo or Lisdexamfetamine Dimesylate for Binge-Eating Disorder: A Randomized Clinical Trial","LIBERATE","Inclusion Criteria:\n\nDisease Characteristics\n\n1. Have a BMI ≥30 kg\u002Fm2 or ≥27 kg\u002Fm2\n\n   * previously diagnosed with at least one obesity-related comorbidity:\n2. Have at least one self-reported unsuccessful dietary effort to lose body weight\n3. Meet Diagnostic and Statistical Manual (DSM)-5 criteria for Binge Eating Disorder (BED) as diagnosed by the Eating Disorder Examination interview and confirmed by binge-eating diaries that is moderate or greater in severity (4 or more episodes per week)\n\n   Participant Characteristics\n4. Are 18 years of age or older\n5. Participants assigned female at birth: (participants assigned female at birth who are not of childbearing potential may participate and include those who are:\n\n   * infertile due to surgical sterilization (hysterectomy, bilateral oophorectomy or tubal ligation), congenital anomaly such as Mullerian agenesis\n   * postmenopausal, defined as either\n   * a female at least 40 years of age with an intact uterus, not on hormone therapy and who has cessation of menses for at least 1 year without an alternative medical cause; women in this category must test negative in pregnancy test prior to study entry OR\n   * a female 55 or older not on hormone therapy, who has had at least 12 months of spontaneous amenorrhea OR\n   * a female at least 55 years of age with a diagnosis of menopause prior to starting hormone replacement therapy\n\n   Participants assigned female at birth of child-bearing potential (not surgically sterilized and between menarche and 1-year postmenopausal) must:\n   * test negative for pregnancy at Visit 1 based on a serum pregnancy test\n   * and if sexually active, agree in writing to use 2 forms of effective contraception, where at least 1 form is highly effective, for the duration of the trial\n   * not be breastfeeding\n\n   Informed Consent\n6. Understand and be willing to comply with all study-related procedures and agree to participate in the study by giving written informed consent in accordance with local regulations\n7. In the investigator's opinion, are well-motivated, capable, and willing to:\n\n   * Learn how to self-inject study drug, as required for this protocol (persons with visual impairments or physical limitations who are not able to perform the injections must have the assistance of an individual trained to inject study drug)\n   * Inject study drug (or receive an injection from a trained individual if visually impaired or with physical limitations)\n   * Learn how to take oral capsules, be consistently able to swallow capsules, and willing to take oral capsules daily as required for this protocol\n   * Follow study procedures for the duration of the study\n\n   Exclusion Criteria:\n\n   Medical Conditions\n\n   Eating disorder-related\n8. Current diagnosis of bulimia nervosa or anorexia nervosa\n\n   Diabetes-related\n9. Have type 1 diabetes mellitus (T1DM) or Type 2 diabetes mellitus (T2DM), history of ketoacidosis, or hyperosmolar state\u002Fcoma\n10. Have laboratory evidence diagnostic of diabetes mellitus during screening, including an HbA1c ≥6.5% or fasting glucose \\>126 mg\u002FdL\n\n    Obesity-related:\n11. Have a self-reported change in body weight \\>5 kg within 3 months prior to screening\n12. Have a prior or planned surgical treatment for obesity (excluding lap-band if removed \\>6 months prior to screening or liposuction or abdominoplasty if performed \\>1 year prior to screening)\n13. Have or plan to have endoscopic and\u002For device-based therapy for obesity or have had device removal within the last 6 months prior to screening (for example, mucosal ablation, gastric artery embolization, intragastric balloon and duodenal-jejunal bypass sleeve)\n\nOther medical\n\n* Have a family or personal history of medullary thyroid carcinoma (MTC) or Multiple Endocrine Neoplasia (MEN) Syndrome type 2\n* Known serious hypersensitivity to tirzepatide or lisdexamfetamine dimesylate or any of the excipients in the medications\n* Have severe gastrointestinal disease\n* Have known clinically significant renal impairment\n* Have uncontrolled medical conditions or contraindications to tirzepatide or lisdexamfetamine dimesylate\n* Have personal or family history of cardiovascular disease that could increase vulnerability to sympathomimetic effects of psychostimulants\n* Have a history of suspected substance abuse within the past 5 years\n* Have a lifetime history of psychostimulant abuse and\u002For dependence\n* Have glaucoma\n* Have had a history of chronic or acute pancreatitis\n* Have obesity induced by other endocrinologic disorders (for example, Cushing Syndrome) or diagnosed monogenetic or syndromic forms of obesity (for example, Melanocortin 4 Receptor deficiency or Prader Willi Syndrome)\n* Have a current diagnosis of attention-deficit\u002Fhyperactivity disorder\n* Have a history of significant active or unstable Major Depressive Disorder (MDD; within the last 2 years) or other severe psychiatric disorder (for example, schizophrenia, bipolar disorder, psychosis, mania, hypomania, or other serious mood or anxiety disorder) Note: Patients with MDD or generalized anxiety disorder whose disease state is considered stable and expected to remain stable throughout the course of the study, in the opinion of the investigator, may be considered for inclusion if not on excluded medications\n* Have a Patient Health Questionnaire-9 (PHQ-9) score of 15 or more at Visit 1 or 2, prior to randomization\n* Have any lifetime history of a suicide attempt\n* Individual is considered a suicide risk in the opinion of the investigator; or endorsement of current, active suicidal ideation at screening or randomization. On the Columbia-Suicide Severity Rating Scale (C-SSRS) at Visits 1 or 2, prior to randomization:\n\n  * a \"yes\" answer to either Question 4 (Active Suicidal Ideation with Some Intent to Act, Without Specific Plan) or\n  * a \"yes\" answer to Question 5 (Active Suicidal Ideation with Specific Plan and Intent) on the \"Suicidal Ideation\" portion of the C-SSRS or\n  * a \"yes\" answer to any of the suicide-related behaviors (Actual Attempt, Interrupted Attempt, Aborted Attempt, Preparatory Act or Behavior) on the \"Suicidal Behavior\" portion of the C-SSRS and\n  * the ideation or behavior occurred within the past month\n* Have taken monoamine oxidate inhibitors (MAOI), or within 14 days of stopping MAOIs\n* Have uncontrolled hypertension (SBP above or equal to 160 mmHg and\u002For diastolic blood pressure above or equal to 100 mmHg)\n* Have any of the following cardiovascular conditions within 3 months prior to randomization: acute myocardial infarction (MI), cerebrovascular accident (stroke), unstable angina\n* Have a history of an active or untreated malignancy or are in remission from a clinically significant malignancy (other than basal- or squamous-cell skin cancer, in situ carcinomas of the cervix, or in situ prostate cancer) for less than 5 years\n* History of seizures (other than infantile febrile seizures), any tic disorder, or a current diagnosis and\u002For known family history of Tourette's Disorder, serious neurological disease, history of significant head trauma, dementia, Parkinson's disease, or intracranial lesions\n* Participant has known history of symptomatic cardiovascular disease, advanced arteriosclerosis, structural cardiac abnormality, cardiomyopathy, serious heart rhythm abnormalities, coronary artery disease, or other serious cardiac problems that may place the participant at increased vulnerability to the sympathomimetic effects of a stimulant medication\n* Have a history of any other condition that, in the opinion of the investigator, may preclude the participant from following and completing the protocol\n\nPrior\u002FConcomitant Therapy\n\n* Are receiving concurrent treatment for eating or weight disorders\n* Use of a psychostimulant within the past 6 months\n* Have taken within 3 months prior to screening, medications (prescribed or over-the counter) intended to promote weight loss. Examples include, but are not limited to\n\n  * Saxenda® (liraglutide 3.0 mg)\n  * Xenical®\u002FAlli® (orlistat)\n  * Meridia® (sibutramine)\n  * Adipex® (phentermine)\n  * BELVIQ® (lorcaserin)\n  * Qsymia® (phentermine\u002Ftopiramate combination)\n  * Contrave® (naltrexone\u002Fbupropion)\n  * Ozempic or Wegovy (semaglutide)\n  * Mounjaro or Zepbound (tirzepatide)\n  * Rybelsus (semaglutide)\n\nPrior\u002FConcurrent Clinical Study Experience\n\n* Are currently enrolled in any other clinical study involving an investigational product (IP) or any other type of medical research judged not to be scientifically or medically compatible with this study",{"count":432,"type":22},105,[99],"The purpose of this study is to assess the efficacy and safety of tirzepatide in adults with obesity and binge-eating disorder, comparing tirzepatide against placebo and lisdexamfetamine dimesylate. All participants will receive guided self-help cognitive behavioral therapy.",[436,28],"Obesity and Overweight",[414,438,439,440],"binge eating disorder","tirzepatide","Lisdexamfetamine","2025-09-17",{"date":443,"type":46},"2025-09-22",{"date":441,"type":46},{"date":446,"type":22},"2027-12-01",{"name":448,"class":53},"Johns Hopkins University",{"id":450,"slug":451,"hasResults":12,"nctId":452,"briefTitle":453,"officialTitle":454,"acronym":455,"eligibilityCriteria":456,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":457,"targetDuration":4,"studyType":459,"phases":4,"briefSummary":460,"conditions":461,"keywords":4,"overallStatus":42,"whyStopped":4,"lastUpdateSubmitDate":464,"lastUpdatePostDateStruct":465,"startDateStruct":467,"completionDateStruct":469,"leadSponsor":471,"locationsCount":54},"100596224","behavioral-therapy-and-glp-1-analogue-effects-on-binge-eating-weight-and-coping-in-obesity-100596224","NCT07042672","Behavioral Therapy and GLP-1 Analogue Effects on Binge Eating, Weight, and Coping in Obesity","Behavioral Therapy With and Without GLP-1 Analogue in Patients With Morbid Obesity and Binge Eating Disorder: A Clinical Prospective Observational Study on Body Weight, Binge Eating Behavior, and Harmful Coping Strategies","BETTER-GLP1","Inclusion criteria\n\n1. Severe obesity defined as BMI \\>40 kg\u002Fm2 or 35 kg\u002Fm2 with obesity-related comorbidities: coronary artery disease, heart failure, hypertension, atrial fibrillation, cerebral stroke, venous thromboembolism, obstructive sleep apnea, obesity hypoventilation syndrome, type 2 diabetes mellitus, non-alcoholic fatty liver disease, dyslipidemia, osteoarthritis and polecystic ovary syndrome\n2. Age between 18 to 65 years\n3. Diagnosis of BED according to DSM-5 criteria\n4. Willingness to participate and provide informed consent\n5. Able to understand and communicate in Norwegian\n\nExclusion criteria\n\n1. Pregnant or lactating women, as well as women planning pregnancy within one year.\n2. Current use medications with major effects on appetite regulation or weight (including, but not limited to systemic glucocorticoids and antipsychotic medication)\n3. Renal failure with estimated glomerular filtration rate less than 30 mL\u002Fmin\u002F1,73m2\n4. Liver failure with either ASAT and\u002For ALAT 5 times upper reference limit, or ALP and\u002For GT more than 3 times upper reference limit, or clinical signs of liver decompensation\n5. Active cancer\n6. Previous medullary thyroid cancer\n7. Previous pancreatitis\n8. Active substance abuse (but previous drug abuse accepted)\n9. Medical or psychological treatment within the specialized health care service for eating disorders within the last 6 months.\n10. Ongoing severe psychiatric disease that makes them unable to follow the lifestyle treatment program\n11. Any illness or prior treatment that in the opinion of the investigator would jeopardize the patient's participation in the study or impact integrity and\u002For quality of study data.\n12. Previous bariatric surgery\n13. Use of appetite suppressing drugs (e.g., GLP-1 analogues and\u002For naltrexone\u002Fbupropion) within the last 6 months\n14. Participation in another clinical study involving an investigational medicinal product within 1 month prior to study inclusion",{"count":458,"type":22},80,"OBSERVATIONAL","This study is a clinical, longitudinal, non-randomized, prospective observational study that seeks to compare the treatment effects and safety of using GLP-1 analogues versus not using appetite suppressants during a lifestyle treatment program that includes individual consultations every fourth month and 10 weeks of CBT-E group therapy in patients with both obesity and BED.\n\nThe primary objective of this study is to evaluate the impact on BED symptomatology, while the secondary objectives include examining the potential adoption of alternative harmful coping mechanisms. Additionally, the study will assess psychological well-being and weight changes and their consequent influence on obesity-associated comorbid conditions.\n\nAdult patients with coexisting obesity and BED presenting at the Obesity clinic at Haukeland University Hospital, Bergen, Norway, will be included Patients will be divided into two groups: Group-GLP1 (n = 40), who will use GLP-1 analogues, and Group-NoMED (n = 40), who will not use appetite suppressants. Both groups will otherwise follow the routine standardized patient care pathway with follow-up controls every four months and participation in CBT group therapy sessions.\n\nChanges in symptoms of BED, alternative harmful coping strategies and mental health will be recorded at baseline and 12 months using patient-reported questionnaires, as well as anthropometric and biochemical data.",[34,28,35,36,462,463,306],"GLP-1","CBT","2025-09-09",{"date":466,"type":46},"2025-09-15",{"date":468,"type":46},"2025-07-01",{"date":470,"type":22},"2028-12-31",{"name":472,"class":53},"Haukeland University Hospital",{"id":474,"slug":475,"hasResults":12,"nctId":476,"briefTitle":477,"officialTitle":478,"acronym":4,"eligibilityCriteria":479,"healthyVolunteers":200,"sex":480,"minAge":18,"maxAge":4,"enrollmentInfo":481,"targetDuration":4,"studyType":23,"phases":482,"briefSummary":483,"conditions":484,"keywords":4,"overallStatus":42,"whyStopped":4,"lastUpdateSubmitDate":486,"lastUpdatePostDateStruct":487,"startDateStruct":489,"completionDateStruct":491,"leadSponsor":492,"locationsCount":54},"100492573","treating-binge-eating-and-obesity-digitally-in-black-women-100492573","NCT05693896","Treating Binge Eating and Obesity Digitally in Black Women","Treating Binge Eating and Obesity Digitally in Black Women: A Feasibility Study","Inclusion Criteria:\n\n* Over 18 years of age,\n* BMI ≥ 30 kg\u002Fm\\^2,\n* have and regularly use a Bluetooth-enabled smartphone,\n* report at least one binge eating episode weekly,\n* work or live within 30 miles of Kannapolis, NC,\n* complete the screening questionnaire\n\nExclusion Criteria:\n\n* currently pregnant,\n* in substance abuse treatment,\n* involved in another weight reduction program,\n* have a history of anorexia,\n* are purging,\n* currently in treatment for eating difficulties,\n* are concurrent intravenous drug users\n* consume \\>4 alcoholic beverages\u002Fday","FEMALE",{"count":97,"type":22},[25],"More than 30% of Black women with obesity binge eat. Binge eating may increase the risk for the development of metabolic syndrome and binge-eating-disorder (BED), which is associated with severe obesity. Though several effective treatments for binge eating exist, Black women have not fared well. Not only has their inclusion in treatment trials been limited, but when participating, they are more likely to drop out, and\u002For lose less weight, compared to their White counterparts. Furthermore, treatment for binge eating is often not available in primary care and community-based settings places where Black women are more likely to receive treatment for their eating and weight-related concerns. Currently, there is scant intervention research to treat binge eating in Black women. With the highest rates of obesity (57%) nationally, Black women are in need of culturally-relevant treatments for binge eating and weight gain prevention. Given the established relationship between frequent binge eating and subsequent weight gain, addressing binge eating among Black women with obesity is imperative.",[32,156,485,311],"Weight Gain Prevention","2025-08-20",{"date":488,"type":46},"2025-08-27",{"date":490,"type":46},"2025-01-15",{"date":115,"type":22},{"name":493,"class":53},"University of North Carolina, Chapel Hill",{"id":495,"slug":496,"hasResults":12,"nctId":497,"briefTitle":498,"officialTitle":499,"acronym":4,"eligibilityCriteria":500,"healthyVolunteers":200,"sex":480,"minAge":18,"maxAge":501,"enrollmentInfo":502,"targetDuration":4,"studyType":23,"phases":504,"briefSummary":505,"conditions":506,"keywords":4,"overallStatus":42,"whyStopped":4,"lastUpdateSubmitDate":508,"lastUpdatePostDateStruct":509,"startDateStruct":511,"completionDateStruct":513,"leadSponsor":515,"locationsCount":54},"100581279","preventing-type-2-diabetes-in-black-emergent-adult-100581279","NCT06848244","Preventing Type 2 Diabetes in Black Emergent Adult","Preventing Type 2 Diabetes in Black Emergent Adult Women At-Risk for Binge-Eating Disorder","Inclusion Criteria:\n\n* Black women\n* between 18-25 years of age\n* BMI ≥ 25 kg\u002Fm\\^2\n* At least one binge eating episode weekly\n* Prediabetic\n* Have access to a smartphone\n\nExclusion Criteria:\n\n* Have no internet access\n* Currently type 2 diabetic\n* Currently pregnant\n* Are in substance use treatment\n* Have received prior or planned bariatric surgery","25 Years",{"count":503,"type":22},100,[25],"Black Americans are disproportionately affected by diabetes, with nearly double the rates of type 2 diabetes mellitus (T2DM), compared to non-Hispanic White adults. Though numerous factors affect these disparities, one modifiable risk factor may be that of binge eating (BE), which increases risk for binge-eating disorder (BED), which is associated with severe obesity, and often precedes a T2DM diagnosis, beginning in childhood or adolescence. Nearly 30% of Black women with obesity report binge eating episodes. Furthermore, given that binge and overeating may disparately increase the odds of obesity in Black adults (15-fold increase vs. 6-fold increase in White adults), reducing this behavior will be critical to prevent continued disparities in T2DM diagnosis. Given that Black women have the highest rates of obesity in the nation (57%), report disparate rates of weight gain between young adulthood and mid adulthood, and report disparate rates of emotional eating in adolescence, which is a risk factor for BE, one pathway to reducing disparities in T2DM risk in Black women may be to reduce binge eating and prevent weight gain in emerging adulthood (ages 18-25).",[507,156,32,311],"Type 2 Diabetes Mellitus","2025-07-28",{"date":510,"type":46},"2025-07-30",{"date":512,"type":46},"2025-06-30",{"date":514,"type":22},"2030-12",{"name":493,"class":53},{"id":517,"slug":518,"hasResults":12,"nctId":519,"briefTitle":520,"officialTitle":520,"acronym":521,"eligibilityCriteria":522,"healthyVolunteers":200,"sex":480,"minAge":18,"maxAge":523,"enrollmentInfo":524,"targetDuration":4,"studyType":23,"phases":525,"briefSummary":526,"conditions":527,"keywords":530,"overallStatus":42,"whyStopped":4,"lastUpdateSubmitDate":534,"lastUpdatePostDateStruct":535,"startDateStruct":537,"completionDateStruct":539,"leadSponsor":541,"locationsCount":543},"100582496","study-of-emotional-regulation-and-underlying-prefrontal-activity-in-binge-eating-disorder-100582496","NCT06864065","Study of Emotional Regulation and Underlying Prefrontal Activity in Binge Eating Disorder","EmoBED","Inclusion Criteria:\n\n* Women between 18 and 60 years old (including 60)\n* Right-handed.\n* For patients only : diagnosed with Binge Eating Desordors according to DSM criteria.\n* Membership of a French social security scheme or beneficiary of such a scheme.\n* Non-opposition of the subject to participate in the study.\n\nNon inclusion Criteria:\n\nHealthy volunteers only :\n\n* Suffering from an eating disorder or any other psychiatric disorder.\n* History of bariatric surgery.\n\nAll subjects (healthy volunteers and patients) :\n\n* Rare obesity (genetic or syndromic).\n* Specific addictions (substances or behaviors).\n* Neurological disorders and\u002For history of stroke or head trauma.\n* Presence of lesions, wounds or dermatitis at the sites where the recording devices are applied.\n* Any serious acute or chronic illness other than the pathology under study, or any treatment likely to interfere with the evaluation of the parameter under study.\n* Inability to follow protocol requirements.\n* Subject unlikely to cooperate with the study and\u002For poor cooperation anticipated by the investigator.\n* Subject unable to speak French and\u002For unable to read.\n* Pregnant or breast-feeding women.\n* Persons deprived of their liberty by judicial or administrative decision; persons under compulsory psychiatric care; persons admitted to a health or social institution for purposes other than research.","60 Years",{"count":458,"type":22},[25],"The goal of this exploratory, interventional, multicentre study is to compare the prefrontal activity during a negative emotion regulation task in women with Binge-Eating Disorder (BED) and healthy women with and without Emotional Eating (EE).\n\nThe aim of this study is to compare the prefrontal processing of cognitive control of emotions between BED and EE and to compare the emotional processing and emotional experience between BED and EE.\n\nThe study will thus compare four experimental groups: patients with BED, BMI-matched healthy volunteers with EE, BMI-matched healthy volunteers, and healthy volunteers of normal weight without BED.\n\nParticipants will perform a down-regulation task of negative emotions elicited by negative pictures. During this task, their cerebral activity will be recorded using functional near-infrared spectroscopy (fNIRS), as well as their autonomous activity (skin conductance, pulse rate, respiration rate).",[156,528,529],"Emotional Eating","Healthy Volunteers",[156,133,531,532,533,528],"fNIRS","Prefrontal cortex","Eating disorder","2025-07-21",{"date":536,"type":46},"2025-07-22",{"date":538,"type":46},"2025-06-24",{"date":540,"type":22},"2026-10-30",{"name":542,"class":53},"Centre Hospitalier Universitaire de Besancon",3,{"id":545,"slug":546,"hasResults":12,"nctId":547,"briefTitle":548,"officialTitle":548,"acronym":549,"eligibilityCriteria":550,"healthyVolunteers":200,"sex":17,"minAge":177,"maxAge":551,"enrollmentInfo":552,"targetDuration":4,"studyType":459,"phases":4,"briefSummary":554,"conditions":555,"keywords":557,"overallStatus":42,"whyStopped":4,"lastUpdateSubmitDate":563,"lastUpdatePostDateStruct":564,"startDateStruct":566,"completionDateStruct":568,"leadSponsor":570,"locationsCount":571},"100561803","eating-disorders-genetics-initiative-2-100561803","NCT06594913","Eating Disorders Genetics Initiative 2","EDGI2","Inclusion Criteria:\n\n* A lifetime history of anorexia nervosa, bulimia nervosa, binge-eating disorder, avoidant restrictive food intake disorders or no history of any disordered eating behavior, based on DSM-5 criteria algorithms\n* Age 12-99 years, depending on country. (US enrollment age is 18-99)\n\nExclusion Criteria:\n\n* History of subthreshold disordered eating behaviors.","99 Years",{"count":553,"type":22},20000,"The overarching intention of the Eating Disorder Genetics Initiative 2 (EDGI2) is to increase sample size, diversity, and eating disorder phenotypes. The investigators are enrolling 20,000 new participants with anorexia nervosa (AN), bulimia nervosa (BN), binge-eating disorder (BED), avoidant\u002Frestrictive food intake disorder (ARFID), and controls in the US, Mexico, Australia, New Zealand, Sweden, and Denmark. A primary study goal is to enroll at least 30% of participants from underrepresented groups. Participants are asked to complete a series of questionnaires and submit a saliva sample for genotyping. The goal is to better understand eating disorders and how they relate to each other so that better treatments can be developed.",[69,70,156,556],"Avoidant Restrictive Food Intake Disorder",[558,559,560,561,562],"severe and enduring eating disorder","genetics","mental health","disordered eating","environmental factors","2025-05-30",{"date":565,"type":46},"2025-05-31",{"date":567,"type":46},"2024-10-28",{"date":569,"type":22},"2027-08-01",{"name":493,"class":53},5,{"id":573,"slug":574,"hasResults":12,"nctId":575,"briefTitle":576,"officialTitle":577,"acronym":578,"eligibilityCriteria":579,"healthyVolunteers":200,"sex":17,"minAge":580,"maxAge":581,"enrollmentInfo":582,"targetDuration":4,"studyType":23,"phases":584,"briefSummary":586,"conditions":587,"keywords":588,"overallStatus":219,"whyStopped":4,"lastUpdateSubmitDate":592,"lastUpdatePostDateStruct":593,"startDateStruct":595,"completionDateStruct":597,"leadSponsor":599,"locationsCount":54},"100579381","phase-1-investigation-of-the-mechanisms-of-the-gut-brain-axis-in-binge-eating-and-obesity-100579381","NCT06823557","Investigation of the Mechanisms of the Gut-brain Axis in Binge Eating and Obesity.","Gut2Brain: Investigation of the Mechanisms of the Gut-brain Axis in Binge Eating and Obesity","Gut2Brain","Inclusion Criteria:\n\n* Portuguese adults (25 with normal weight; 25 with obesity only (30 ≤ BMI \\\u003C 40) and BED; 54 with BED)\n* Residents in Portugal for the past 10 years\n\nExclusion Criteria:\n\n* Significant weight loss (\\>5% of body weight) in the past 2 years\n* Antibiotic use in the past 6 months\n* History of surgery or medical\u002Fpsychiatric diseases\n* Pregnant or breastfeeding\n* History of drug use or dependence\n* Use of medications that impact weight\n* Have metal implants or pacemakers","20 Years","45 Years",{"count":583,"type":22},104,[585],"PHASE1","Binge Eating Disorder (BED) is a recently recognized eating disorder, characterized by recurrent episodes of overeating with a loss of control. Highly comorbid with obesity, BED is associated with poor outcomes in weight loss treatments and presents unique challenges due to its distinct neuro-psycho-biological mechanisms, which remain poorly understood. The Microbiota-Gut-Brain Axis (MGBA) is a bidirectional communication system linking the gut microbiota with the central nervous system, that plays a critical role in regulating appetite, mood, and eating behavior. Dysregulations in MGBA may contribute to the development and maintenance of BED, offering a novel framework for understanding its complex mechanisms and identifying new therapeutic targets. Psychobiotics -pre-, pro-, or symbiotics that modulate the microbiota- emerge as a promising treatment strategy to address BED symptoms by influencing MGBA activity.\n\nThe goal of this randomized clinical trial (RCT) is to investigate the role of psychobiotics in modulating the gut-brain axis and improving binge eating in adults, with a particular focus on evaluating these effects independently of obesity status. This project stands out for its comprehensive approach to understanding BED, integrating psychological, neurofunctional, hormonal, and microbiota factors that contribute to this complex disorder.\n\nThe main questions it aims to answer are:\n\n* What specific alterations in the MGBA pathways are associated with BED?\n* Can psychobiotic supplementation effectively reverse microbiota alterations and modulate MGBA activity, ultimately improving BED symptoms? Researchers will compare participants receiving psychobiotics to those receiving a look-alike substance that contains no drug (a placebo) to evaluate whether psychobiotics impact endocrine hormones, neurofunction, psychological and behavioral factors related to eating regulation, and BED symptoms.\n\nParticipants will:\n\n* Undergo an assessment protocol that includes microbiota sampling, blood tests for hormone analysis, neurofunctional evaluations, and psychological\u002Fbehavioral assessments before and after the psychobiotics\u002F placebo intervention.\n* Take psychobiotics or a placebo daily for 12 weeks and receive well-being monitoring\n* Participate in follow-up visits three months after the intervention to monitor changes in BED symptoms and related parameters.",[28,311],[589,590,591,311,215],"psychobiotic treatment","Study of neuro-psycho-biological mechanisms","Microbiota-Gut-Brain Axis (MGBA)","2025-03-24",{"date":594,"type":46},"2025-03-28",{"date":596,"type":22},"2025-04",{"date":598,"type":22},"2030-03",{"name":600,"class":53},"Universidade do Porto",{"id":602,"slug":603,"hasResults":12,"nctId":604,"briefTitle":605,"officialTitle":605,"acronym":4,"eligibilityCriteria":606,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":63,"enrollmentInfo":607,"targetDuration":4,"studyType":23,"phases":608,"briefSummary":609,"conditions":610,"keywords":611,"overallStatus":42,"whyStopped":4,"lastUpdateSubmitDate":614,"lastUpdatePostDateStruct":615,"startDateStruct":617,"completionDateStruct":619,"leadSponsor":620,"locationsCount":54},"100578943","phase-1-a-self-guided-mobile-intervention-for-adults-with-binge-eating-and-obesity-100578943","NCT06817863","A Self-Guided Mobile Intervention for Adults With Binge Eating and Obesity","Inclusion Criteria:\n\n1. Are English speaking male or female\n2. Are aged 18-70 years\n3. Have recurrent objective or subjective binge eating episodes (≥12 episodes in 3 months)\n4. Have BMI ≥30\n5. Own an iPhone with iOS 11 or higher, or Android with OS 8.1 or higher\n6. Are willing and able to complete enrollment procedures\n7. Are able to understand the nature of the study and provide written informed consent\n\nExclusion Criteria:\n\n1. Are unable to fluently speak, write and read English.\n2. Are already receiving treatment for an eating disorder (e.g., research participants cannot be receiving concurrent eating disorder treatment from another provider)\n3. Are receiving weight loss treatment (behavioral or pharmacological)\n4. Have a mental handicap or are currently experiencing severe psychopathology that would limit their ability to engage in study (e.g., imminent or high risk for suicide, substance use disorder, active psychotic disorder,)\n5. Are purging and\u002For using laxatives 3 or more times per week and are not deemed safe for remote treatment by a primary care provider.\n6. Are exercising 2 or more hours a day on average, or engaging in significantly harmful compensatory behaviors (i.e., \\> 3x\u002Fweek of self-induced vomiting or laxative use), and are not deemed safe for remote treatment by a primary care provider.\n7. Are fasting for 24 hours or more, \\> 3x times a week, and are not deemed safe for remote treatment by a primary care provider.\n8. Are unwilling to receive medical clearance and\u002For medical monitoring as requested by the study to ensure they are medically safe to participate.\n9. Are pregnant or planning to become pregnant within the next year.\n10. Are individuals who are not yet adults (infants, children, teenagers) Are currently taking any of these medications: Haldol, Loxitane, Mellaril, Moban, Navane, Prolixin, Serentil, Stelaxine, Trilafon, Thoraxine, Abilify, Clozaril, Geodon, Risperdal, Seroquel, Zyprexa\n11. Are adults unable to consent\n12. Are prisoners",{"count":5,"type":22},[585,99],"The proposed study is an open label, non randomized, waitlist controlled single group feasibility study of the feasibility and usability of a digital intervention (called ChangeBite) to be used by individuals with obesity and comorbid binge eating behavior. The proposed research will include approximately 30 participants. Participants will be recruited for this single group pilot trial using online advertising to attend a virtual screening session. Screened participants willing and eligible to participate, will receive informed consent and formally start ChangeBite. Participants will be instructed to engage with ChangeBite and attend follow up assessments on scheduled video calls. Feasibility and acceptability of implementation will be assessed by collecting data on recruitment, retention, usability and satisfaction. The research team will also collect assessment data from participants on feasibility, and usability. In addition to self report scales, semi-structured interviews will be completed with a trained research team member via video call and will be partially recorded. Assessments will be done at baseline, 12 weeks, and 24 weeks. Participants' app use frequency and duration will be tracked using software analytics. Participants' body weight will be captured weekly using a timestamped picture of their weight as it appears on their scale and Body Mass Index will be calculated with these data points.",[34,28],[612,613,73],"digital treatment","self-help intervention","2025-02-13",{"date":616,"type":46},"2025-02-17",{"date":618,"type":22},"2025-02",{"date":374,"type":22},{"name":621,"class":53},"Drexel University",{"id":623,"slug":624,"hasResults":12,"nctId":625,"briefTitle":626,"officialTitle":627,"acronym":628,"eligibilityCriteria":629,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":630,"targetDuration":4,"studyType":459,"phases":4,"briefSummary":632,"conditions":633,"keywords":638,"overallStatus":42,"whyStopped":4,"lastUpdateSubmitDate":643,"lastUpdatePostDateStruct":644,"startDateStruct":646,"completionDateStruct":648,"leadSponsor":650,"locationsCount":543},"100495095","profiling-the-dynamic-of-binge-eating-disorder-prody-bed-100495095","NCT05726721","Profiling the Dynamic of Binge Eating Disorder (PRODY-BED)","Profiling the Dynamic of Binge Eating Disorder (BED): a Longitudinal Study Examining the Influence of Emotion Regulation, Executive Function, Eating Pattern on BED and Outcome (PRODY-BED)","PRODY-BED","Inclusion Criteria:\n\n* Age 18+,\n* diagnosed with Binge eating Disorder,\n* and offered treatment at on of the inclusion sites.\n\nExclusion Criteria:\n\n* Severe psychiatric comorbidity (e.g. psychosis, severe developmental disorder, severe cogntive impairement)",{"count":631,"type":22},180,"The goal of this observational study is to explore if different and specific profiles can be identified in adults with binge eating disorder (BED) depending on their additional eating pathology, emotion regulation and executive functions. The main questions it aims to answer are:\n\n* Is there different and specific subgroups of patients with BED according to baseline profiles in emotion regulation, executive function and additional eating pathology (including restriction, chaotic eating, grazing and eating on external cues)?\n* Are subgroups of individuals with BED (based on identified profiles) associated with outcome at end of treatment and follow-up?\n* What is the trajectories in remission rates of specific symptom dimensions (eating disorder pathology, emotion regulation, executive function, and depressive symptoms) in individuals with BED and is there specific trajectory profiles in these dimensions?\n* Is early changes in specific symptom dimensions (eating pathology, emotion regulation, executive function, or depression) associated with outcome of BED? Participants will be asked to fill in questionnaires before treatment as usual, 10 weeks into treatment, at end of treatment and at 6- and 12-month follow-up.",[156,634,635,636,637],"Emotion Regulation","Executive Dysfunction","Eating Behavior","Depressive Symptoms",[639,640,438,641,642],"psychotherapy","Adults","emotion regulation","executive function","2025-02-04",{"date":645,"type":46},"2025-02-06",{"date":647,"type":46},"2023-07-03",{"date":649,"type":22},"2028-05-31",{"name":651,"class":53},"Aarhus University Hospital",{"id":653,"slug":654,"hasResults":12,"nctId":655,"briefTitle":656,"officialTitle":656,"acronym":657,"eligibilityCriteria":658,"healthyVolunteers":12,"sex":17,"minAge":202,"maxAge":4,"enrollmentInfo":659,"targetDuration":580,"studyType":459,"phases":4,"briefSummary":661,"conditions":662,"keywords":4,"overallStatus":42,"whyStopped":4,"lastUpdateSubmitDate":663,"lastUpdatePostDateStruct":664,"startDateStruct":666,"completionDateStruct":668,"leadSponsor":670,"locationsCount":54},"100573901","a-longitudinal-study-of-severe-and-enduring-eating-disorders-100573901","NCT06752304","A Longitudinal Study of Severe and Enduring Eating Disorders","Long-SEED","Inclusion criteria:\n\n* found to meet the criteria for an eating disorder\n* being in need of treatment\n* having provided written informed consent (for minors, this includes consent from all caregivers and the minors themselves).\n\nExclusion criteria:\n\n* Eating disorders symptoms in need of emergency care\n* High risk for suicide\n* An inability to respond to the questionnaires due to e.g., lack of knowledge in Swedish.",{"count":660,"type":22},800,"The goal of this observational longitudinal study is to investigate characteristics and factors associated with the development of Severe and Enduring Eating Disorders (SEED). In this project, the researchers will follow two prospective cohorts of patients with eating disorders (ED), one adolescent (ages 14-17) and one adult (ages 18+), in terms of change in and impact of clinical, psychological, and biological risk factors.\n\nData will be collected at baseline, after treatment, two years after baseline, and thereafter five, 10 and 20 years after baseline. Participants will be asked to undergo a physical examination, leave blood samples, be interviewed, and fill in questionnaires. If the participants are minors, their care takers will also fill in the questionnaires.\n\nThe study aims to explore how clinical, psychological, and biological risk factors-including comorbidity, personality characteristics, difficulties with emotion regulation (ER), cognitive inflexibility, loneliness, severe ED symptoms, and inflammatory activation-contribute to a chronic course of the disorder.",[36,69,70,28,71],"2024-12-28",{"date":665,"type":46},"2024-12-31",{"date":667,"type":46},"2024-09-01",{"date":669,"type":22},"2048-12",{"name":671,"class":53},"Uppsala University Hospital",{"id":673,"slug":674,"hasResults":12,"nctId":675,"briefTitle":676,"officialTitle":677,"acronym":4,"eligibilityCriteria":678,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":679,"targetDuration":4,"studyType":459,"phases":4,"briefSummary":680,"conditions":681,"keywords":682,"overallStatus":42,"whyStopped":4,"lastUpdateSubmitDate":686,"lastUpdatePostDateStruct":687,"startDateStruct":689,"completionDateStruct":690,"leadSponsor":692,"locationsCount":229},"100450773","compuls-bed-severity-100450773","NCT05149859","Compuls-BED-Severity","Reconsidering Severity Classification for Binge Eating Disorder (BED): the Role of Impulsivity, Compulsivity and Co-occurring Disorders","Inclusion Criteria:\n\n* men or women aged 1\n* participants eligible for bariatric surgery (BMI\\>40, or BMI\\>35 with severe comorbidities)\n* participants scheduled for medical evaluation and treatment of obesity at the IUCPQ Obesity Clinic (BMI≥30)\n* participants scheduled for evaluation and treatment of BED at the CEPIA with obesity (BMI≥30)\n* for the group with BED: positive BEDS-7 screen and Binge Eating Scale score \\>16;\n* for the control group: have a negative BEDS-7 screen and Binge Eating Scale score\\\u003C12\n* be fluent in French and able to consent.\n\nExclusion criteria :\n\n* participants with severe neurological disorder and\u002For major neurocognitive deficits;\n* participants with previous bariatric surgery or with introduction or change of anti-obesity medication (liraglutide or naltrexone\u002Fbupropion) in the previous 3 months;\n* participants who cannot read and\u002For understand French;\n* participants under guardianship or curatorship;\n* participants already included in a study with a conflict of interest with this study;\n* inability to use a computer or iPad;\n* inability to access an Internet connection or to visit one of the inclusion sites.\n\nSecondary exclusion criteria:\n\n* participants with a discordance between BEDS-7 (positive) and Binge Eating Scale (score ≤ 16) results found secondarily\n* participants who did not participate in part of the assessments (e.g., self-questionnaires or neurocognitive tests) and participants with a rate of missing data\\>10%.",{"count":204,"type":22},"* Binge Eating Disorder (BED) has been fairly recently introduced into the Diagnostic and Statistical Manual 5 psychiatric classification and its severity criteria are still not well established.\n* Moreover, it remains unclear whether BED is associated with greater metabolic severity or more somatic comorbidities, especially in obesity.\n* Improved BED severity staging could lead to a better definition of management strategies and , therefore, facilitate screening and care.\n\nThe investigators' hypothesis is that an improved assessment of the impulsivity-compulsivity spectrum, emotional regulation, attentional impairment and somatic or psychiatric comorbidities will result in a better distinction between the severe form of BED (e.g., highly impulsive and somatically complicated) from milder form (e.g., more compulsive and less somatically complicated).",[156],[156,683,311,684,685],"Impulsivity","Attention","Emotional regulation","2024-10-07",{"date":688,"type":46},"2024-10-09",{"date":113,"type":46},{"date":691,"type":22},"2025-12-31",{"name":693,"class":53},"Laval University"]